RAPT Therapeutics Inc

RAPT Therapeutics insider sales reveal how a $58‑per‑share merger with GSK can shift short‑term price dynamics and long‑term growth prospects. Find out what investors should track for true value.

RAPT Therapeutics’ insider sale ties into its merger with GSK‑linked Redrose, revealing structured RSU exits, robust reimbursement gains, and 12‑18 month clinical‑speed‑up prospects.